Biocon, a top big biotech enterprise is now close to inking a pharma partners deal with US-based biopharmaceuticals giant Bristol-Myers Squibb, to partner for the development and commercialization of its oral insulin product IN-105, which is currently undergoing late-stage clinical trials.
Biocon is unlikely to receive any upfront payment as part of the pharma partners agreement that it is close to reaching with Bristol-Myers Squibb, but the latter is likely to make payments to Biocon on the basis of certain milestones being achieved once the drug is close to completing phase III clinical trials.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Diabetes Partnering
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity